This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Lannett Company Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Lannett Company.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Pharmaceuticals earnings growth	20.8%
Revenue growth rate	n/a
Future return on equity	n/a
Analyst coverage	None
Last updated	n/a

Recent future growth updates

Recent updates

Analysts Just Made A Major Revision To Their Lannett Company, Inc. (NYSE:LCI) Revenue Forecasts

Feb 05

A Look At The Fair Value Of Lannett Company, Inc. (NYSE:LCI)

Nov 05

Is Lannett Company (NYSE:LCI) A Risky Investment?

Jun 20

Lannett down 5.5%, SVC gains 5.7% as S&P 500 makes room for Organon

May 27

Is Lannett Company (NYSE:LCI) A Risky Investment?

Mar 18

Independent Director David Drabik Just Sold A Bunch Of Shares In Lannett Company, Inc. (NYSE:LCI)

Feb 11

Lannett shares slide on 2021 forecast cut, QF2 topline fall

Feb 04

What Type Of Returns Would Lannett Company's(NYSE:LCI) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?

Jan 15

Is Lannett Company (NYSE:LCI) Using Too Much Debt?

Dec 11

Lannett pays off remaining $42M in outstanding loans

Nov 30

Lannett launches authorized generic of Tirosint

Nov 03

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Lannett Company has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

OTCPK:LCIN.Q - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
3/31/2023	311	-259	-65	-57	N/A
12/31/2022	309	-193	-60	-51	N/A
9/30/2022	314	-237	-44	-36	N/A
6/30/2022	341	-232	-18	-7	N/A
3/31/2022	372	-316	24	39	N/A
12/31/2021	406	-288	85	99	N/A
9/30/2021	454	-379	77	90	N/A
6/30/2021	479	-363	46	61	N/A
3/31/2021	511	-195	82	100	N/A
12/31/2020	543	-205	23	44	N/A
9/30/2020	545	-28	74	100	N/A
6/30/2020	546	-33	69	116	N/A
3/31/2020	542	-31	-3	45	N/A
12/31/2019	570	-4	81	130	N/A
9/30/2019	628	3	77	126	N/A
6/30/2019	655	-272	149	176	N/A
3/31/2019	692	-276	153	197	N/A
12/31/2018	694	-274	79	136	N/A
9/30/2018	685	-272	112	175	N/A
6/30/2018	685	29	47	119	N/A
3/31/2018	653	46	84	148	N/A
12/31/2017	644	48	118	174	N/A
9/30/2017	631	42	75	127	N/A
6/30/2017	637	-1	117	165	N/A
3/31/2017	667	-3	93	133	N/A
12/31/2016	665	-23	N/A	141	N/A
9/30/2016	621	-18	N/A	156	N/A
6/30/2016	566	45	N/A	135	N/A
3/31/2016	496	75	N/A	162	N/A
12/31/2015	432	117	N/A	138	N/A
9/30/2015	420	148	N/A	130	N/A
6/30/2015	407	150	N/A	129	N/A
3/31/2015	388	140	N/A	119	N/A
12/31/2014	369	126	N/A	97	N/A
9/30/2014	321	98	N/A	64	N/A
6/30/2014	274	57	N/A	45	N/A
3/31/2014	233	37	N/A	29	N/A
12/31/2013	192	18	N/A	14	N/A
9/30/2013	162	4	N/A	19	N/A
6/30/2013	151	13	N/A	27	N/A
3/31/2013	147	11	N/A	20	N/A
12/31/2012	138	9	N/A	20	N/A
9/30/2012	129	7	N/A	14	N/A
6/30/2012	123	4	N/A	11	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if LCIN.Q's forecast earnings growth is above the savings rate (2.1%).

Earnings vs Market: Insufficient data to determine if LCIN.Q's earnings are forecast to grow faster than the US market

High Growth Earnings: Insufficient data to determine if LCIN.Q's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if LCIN.Q's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if LCIN.Q's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if LCIN.Q's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

This company listing is no longer active

Lannett Company Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Price target decreased to US$1.00

Consensus revenue estimates fall by 16%

Lannett Company, Inc. Revises Earnings Guidance for the Fiscal Year 2022

Price target decreased to US$3.00

Lannett Company, Inc. Revises Earnings Guidance for the Fiscal Year 2022

Price target decreased to US$5.00

Recent updates

Lannett Company, Inc. Files Form 15

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Lannett Company, Inc. Reports Asset Impairment for the Second Quarter Ended December 31, 2022

Lannett Company, Inc. to Report Q2, 2023 Results on Feb 01, 2023

Lannett announces 1-for-4 reverse stock split

Lannett Company Provides Development Update on Biosimilar Insulin Products

Lannett Company, Inc., Annual General Meeting, Jan 25, 2023

Price target decreased to US$1.00

Insufficient new directors

Lannett gains on patent deal for biosimilar insulin device

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Lannett Company, Inc. Reports Asset Impairment Charges for the First Quarter Ended September 30, 2022; Reiterates Asset Impairment Charges Guidance for the Year 2023

Lannett Company, Inc. to Report Q1, 2023 Results on Nov 02, 2022

Lannett Company, Inc. Receives FDA Approval to Manufacture Numbrino® at Seymour Plant

Lannett gets FDA approval to manufacture Numbrino® at Seymour plant

Consensus revenue estimates fall by 16%

Lannett Company, Inc. (NYSE:LCI) Analysts Just Slashed This Year's Estimates

Lannett Company, Inc. Announces Subject Dosing Complete for Pivotal Clinical Trial of Biosimilar Insulin Glargine

Full year 2022 earnings: EPS misses analyst expectations

Lannett Company, Inc. Announces Impairment Charges for the Fourth Quarter Ended June 30, 2022

Lannett GAAP EPS of -$2.30, revenue of $74.19M

Lannett Company, Inc. to Report Q4, 2022 Results on Aug 24, 2022

Insufficient new directors

Lannett Company, Inc. Provides Update on Pivotal Clinical Trial for Biosimilar Insulin Glargine

Lannett Company Receives Notice from the NYSE Accepting the Company's Plan for NYSE's Listed Company Manual

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Lannett Company, Inc. Revises Earnings Guidance for the Fiscal Year 2022

Price target decreased to US$3.00

Lannett Company, Inc. Initiates Pivotal Clinical Trial for Biosimilar Insulin Glargine

Lannett: A Self-Inflicted Crisis

Lannett Company, Inc. Revises Earnings Guidance for the Fiscal Year 2022

Analysts Just Made A Major Revision To Their Lannett Company, Inc. (NYSE:LCI) Revenue Forecasts

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Lannett Company, Inc. to Report Q2, 2022 Results on Feb 03, 2022

Lannett Announces FDA Completes Review of Investigational New Drug Application for Biosimilar Insulin Glargine

Lannett Announces Submission of Investigational New Drug (Ind) Application for Biosimilar Insulin Glargine

Non-Executive Independent Chairman recently bought US$86k worth of stock

First quarter 2022 earnings released: US$0.56 loss per share (vs US$0.17 loss in 1Q 2021)

A Look At The Fair Value Of Lannett Company, Inc. (NYSE:LCI)

Price target decreased to US$5.00

Independent Director recently sold US$81k worth of stock

Independent Director notifies of intention to sell stock

Full year 2021 earnings released: US$9.23 loss per share (vs US$0.86 loss in FY 2020)

Price target increased to US$7.00

Lannett Company, Inc. Provides Earnings Guidance for the Fiscal Year 2022

Insufficient new directors

Lannett Company, Inc. Launches Fluvastatin Sodium ER Tablets

Lannett Company, Inc.(NYSE:LCI) dropped from Russell 2000 Dynamic Index

Is Lannett Company (NYSE:LCI) A Risky Investment?

Lannett Announces FDA Acceptance, as a Priority Original Anda, of the Generic Advair Diskus Filing

Lannett down 5.5%, SVC gains 5.7% as S&P 500 makes room for Organon

Non-Executive Independent Chairman recently bought US$84k worth of stock

Price target decreased to US$5.88

Third quarter 2021 earnings released: US$0.18 loss per share (vs US$0.43 loss in 3Q 2020)

Lannett Company, Inc. Provides Earnings Guidance for the Fiscal Year 2021

Is Lannett Company (NYSE:LCI) A Risky Investment?

Lannett Development Of Biosimilar Insulin Glargine Product Continues To Advance

New 90-day low: US$5.93

Independent Director recently sold US$203k worth of stock

Independent Director David Drabik Just Sold A Bunch Of Shares In Lannett Company, Inc. (NYSE:LCI)

Lannett Company, Inc. Enters into Collaboration and License Agreement and Supply Agreement with Sunshine Lake Pharma Co., Ltd

Lannett Company, Inc. Begins Marketing Chlorpromazine Hydrochloride Tablets

Second quarter 2021 earnings released: US$4.36 loss per share (vs US$0.13 profit in 2Q 2020)

Revenue and earnings beat expectations

Lannett Company, Inc. Revises Guidance for Fiscal Year 2021

Lannett shares slide on 2021 forecast cut, QF2 topline fall

Lannett Company, Inc. to Report Q2, 2021 Results on Feb 03, 2021

New 90-day high: US$7.93